Guidance and quality standards awaiting development | Guidance

Showing 211 to 220 of 381

Guidance and quality standards awaiting development
Title	Type
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance
Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]	Technology appraisal guidance
Olezarsen for treating severe hypertriglyceridaemia [GID-TA12016]	Technology appraisal guidance
Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [GID-TA12001]	Technology appraisal guidance
Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [GID-TA12003]	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance
Orforglipron for managing overweight and obesity in people 12 to 17 years	Technology appraisal guidance
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [ID6706]	Technology appraisal guidance
Osimertinib for adjuvant treatment of EGFR mutation-positive stage 1A2 or 1A3 non-small-cell lung cancer after complete tumour resection	Technology appraisal guidance